Details of the Drug Combination

General Information of Drug Combination (ID: DC2MNA6)

Drug Combination Name
Goserelin Dutasteride
Indication
Disease Entry Status REF
Salivary Duct Carcinoma Phase 2 [1]
Component Drugs Goserelin   DMAT8CG Dutasteride   DMQ4TJK
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Goserelin
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Approved [2]
Estrogen-receptor positive breast cancer N.A. Approved [3]
Endometriosis GA10 Investigative [3]
Male breast carcinoma N.A. Investigative [3]
Goserelin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Leutinizing-hormone-releasing hormone (GNRH1) TT0ID4A GON1_HUMAN Activator [6]
------------------------------------------------------------------------------------
Goserelin Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Follitropin subunit beta (FSHB) OTGLS283 FSHB_HUMAN Decreases Expression [7]
------------------------------------------------------------------------------------
Indication(s) of Dutasteride
Disease Entry ICD 11 Status REF
Benign prostatic hyperplasia GA90 Approved [4]
Prostate adenocarcinoma N.A. Approved [5]
Prostate cancer 2C82.0 Phase 3 [4]
Dutasteride Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A) TT2A0DR S5A1_HUMAN; S5A2_HUMAN; PORED_HUMAN Inhibitor [9]
------------------------------------------------------------------------------------
Dutasteride Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [10]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [11]
------------------------------------------------------------------------------------
Dutasteride Interacts with 10 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Aldo-keto reductase family 1 member C3 (AKR1C3) OTU2SXBA AK1C3_HUMAN Increases Expression [12]
Aldo-keto reductase family 1 member C2 (AKR1C2) OTQ2XMO3 AK1C2_HUMAN Increases Expression [12]
Aldo-keto reductase family 1 member C1 (AKR1C1) OTQKR4CM AK1C1_HUMAN Increases Expression [12]
Receptor tyrosine-protein kinase erbB-2 (ERBB2) OTOAUNCK ERBB2_HUMAN Increases Expression [8]
17-beta-hydroxysteroid dehydrogenase type 1 (HSD17B1) OT6EBDHM DHB1_HUMAN Increases Expression [8]
Kallikrein-2 (KLK2) OT9RE37R KLK2_HUMAN Decreases Expression [8]
17-beta-hydroxysteroid dehydrogenase type 3 (HSD17B3) OT45D396 DHB3_HUMAN Increases Expression [8]
Son of sevenless homolog 1 (SOS1) OTTCWXC3 SOS1_HUMAN Increases Expression [8]
ELL-associated factor 2 (EAF2) OTSOET5L EAF2_HUMAN Decreases Expression [13]
Acireductone dioxygenase (ADI1) OT8IOD03 MTND_HUMAN Decreases Expression [13]
------------------------------------------------------------------------------------
⏷ Show the Full List of 10 DOT(s)

References

1 ClinicalTrials.gov (NCT05513365) Phase II Dutasteride in Combination With CAB vs CAB in SDC
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3879).
3 Goserelin FDA Label
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7457).
5 Dutasteride FDA Label
6 Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):341-9.
7 [Kuntai capsule combined with gonadotropin releasing hormone agonist in treatment of moderate-severe endometriosis: a clinical observation]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2014 Nov;34(11):1288-91.
8 Effects of dutasteride on the expression of genes related to androgen metabolism and related pathway in human prostate cancer cell lines. Invest New Drugs. 2007 Oct;25(5):491-7.
9 The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme Can Urol Assoc J. 2009 Jun;3(3 Suppl 2):S109-14.
10 Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2011 May;50(5):281-94.
11 Product monograph: Avodart (dutasteride capsules).
12 Dutasteride affects progesterone metabolizing enzyme activity/expression in human breast cell lines resulting in suppression of cell proliferation and detachment. J Steroid Biochem Mol Biol. 2006 Aug;100(4-5):129-40.
13 Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice. Prostate. 2010 Oct 1;70(14):1575-85. doi: 10.1002/pros.21193.